Alexion Pharmaceuticals, Inc.’s Post

𝐖𝐞'𝐯𝐞 𝐞𝐱𝐩𝐚𝐧𝐝𝐞𝐝 𝐨𝐮𝐫 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩 𝐰𝐢𝐭𝐡 Roche Danmark – 𝐚𝐢𝐦𝐢𝐧𝐠 𝐭𝐨 𝐝𝐫𝐢𝐯𝐞 𝐞𝐯𝐞𝐧 𝐦𝐨𝐫𝐞 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 🚀 🤝 Last week, BETA. HEALTH and Roche shook hands on a shared ambition to pursue more industry-connected corporate partners to join our healthcare innovation efforts. We believe that this path forward will make our impact even greater! Roche has shown us that the industry has unlimited capabilities that can benefit the development, implementation and scaling of innovative clinical solutions – and together, we believe that more BETA. HEALTH-funded projects should benefit from extended partnerships. Our partnership began last summer when we joined forces to create an 'Industry Call' pilot programme aimed at further accelerating clinical innovation. The selected project, cancercare@home, aims to increase care capacity while improving quality of life for cancer patients by enabling them to self-test their blood values at home. The joint programme has connected the cancercare@home team with Roche’s global network of industry experts, who are using their experience and connections to help bring this point-of-care technology to patients. 𝐑𝐞𝐚𝐝 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐞 ‘𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐂𝐚𝐥𝐥’ 👉 https://lnkd.in/e3TvnU_i Christian Juul-Nielsen, Rasmus Fält, Agnete Halldorsson, Mikkel Møl Dalsgaard, Bodil Christine Reumert, Sarah Maria Rasch, Rasmus Thomsen, Rasmus Bjørn Dahl

The BIO International Convention 2024, held in San Diego, has concluded with remarkable success, leaving attendees inspired and optimistic about the future of the biotechnology and life sciences industry. This year’s convention brought together over 20,000 professionals from around the globe, from researchers starting out on their journey’s to industry leading c-suites from around the globe. Follow the link for the key highlights from this year’s event - including several high-profile keynote speakers who provided insightful perspectives on the future of biotechnology. These included: Dr. Jennifer Doudna, Nobel laureate and co-inventor of CRISPR technology, who discussed the latest advancements in gene editing and its potential to revolutionize medicine. Albert Bourla, CEO of Pfizer, who shared the company’s vision for the next decade, emphasizing the role of mRNA technology beyond COVID-19 vaccines. Francis Collins, former director of the National Institutes of Health, who highlighted the importance of global collaboration in addressing pandemics and other health crises. The exhibition hall was a bustling hub of activity, with over 1,800 exhibitors showcasing their latest products and technologies. Attendees also had the opportunity to participate in over 500 sessions, including panel discussions and workshops that covered a wide array of topics. Key sessions focused on: The Future of Digital Health: Exploring how digital tools and AI are transforming healthcare delivery and patient care. Sustainability in Biotechnology: Addressing the environmental impact of biomanufacturing and the steps companies can take to become more sustainable. Diversity and Inclusion in Life Sciences: Strategies to foster a more inclusive workforce and the benefits of diversity in driving innovation. Cpl Life Sciences US played an active role in this year’s convention, showcasing our latest staffing solutions and engaging in meaningful discussions about the future of the life sciences workforce. Highlights from our participation included U.S VP Tom Hancox panel contribution on how to approach your clinical development strategy in the U.S alongside François Ravenelle (CEO of Inversago Pharma), Vanessa Elharrar MD MPH (Global Medical Officer at PPD) & James Ravitz (FDA Lead & Partner at McDermott Will & Emery). The Bio International Convention 2024 has once again proven to be an essential event for anyone involved in the life sciences industry. The innovative ideas, strategic partnerships, and inspiring discussions that emerged from this year’s event will undoubtedly shape the future of biotechnology and healthcare. https://lnkd.in/eKhMvhEh

Last Friday, I was privileged to witness the 100th anniversary of Roche in Belgium. It was an absolute honor to be a keynote speaker at their celebration event, and the perfect moment to take a step back and reflect on Roche's remarkable journey, and their enduring commitment to advancing healthcare in Belgium. I was inspired to see how they too have been at the forefront of addressing critical healthcare challenges with their innovations in diagnostics and medicines. It reminds me that pharma and biotech companies might have different approaches - sometimes as partners, sometimes as competitors - but we’re always united by our commitment to transforming patient outcomes and improving quality of life. Prevention, early diagnosis and rapid access to innovative treatments: it’s what keeps us moving forward, and it’s our industry’s responsibility to society. So, I echo today’s call for faster and easier access to innovation for patients, and for an effective healthcare spending. We’ll need a stable policy and investment climate and we need to move away from silos. I heard a clear call for policies, frameworks, and infrastructure to ensure that high quality data can be securely shared between stakeholders and across projects to enable personalized care. It’s a critical knot to untangle, as it’s a cornerstone for future-proof healthcare. As we look to the future together, I’m confident that collaborations between industry leaders like Roche, innovative biotech companies like Galapagos, and Belgium’s world-class academic centers will continue to drive progress and shape the future of healthcare - in Belgium and beyond – provided that we can operate in a stable and supportive climate for innovation. Congratulations once again to Roche Belgium & Luxembourg and Roche Diagnostics Belgium on this momentous milestone. Here's to the next hundred years of advancing healthcare together! #CloseTheHealthcareGap #Roche100yinBE #PioneeringForPatients

Recently, I had the privilege of attending a compelling event, I would like to thank MassBio for the invite, the event was sponsored by Alexion Pharmaceuticals, Inc. and organized by New England Council, centered around the theme "New England Innovates: Tackling Rare Diseases." James (Jim) T. Brett. President New England Council, shed light on the profound challenge posed by the approximately 10,000 known rare diseases, with a staggering 90% lacking approved therapies. U.S. Representative Jake Auchincloss delivered an insightful keynote, highlighting the pivotal role of the biotech sector in driving the U.S. economy forward. He underscored the inherently probabilistic nature of biological research and emphasized the urgent need to attract skilled talent through enhanced immigration policies. The discussion delved into the hurdles hindering the commercialization of rare disease treatments, with panelists like Irene Abrams of Boston Children's Hospital advocating for increased incentives and partnerships within the industry. Duane Clark from Sanofi accentuated Cambridge's status as an epicenter of innovation, owing to robust research investments and the presence of renowned academic institutions like Harvard University and MIT. Betsy O'Neill of Amgen underscored the vibrant ecosystem in New England, fostering not only groundbreaking research but also providing robust support through venture capital and legal expertise. Heidi Ross from the National Organization for Rare Disorders emphasized the imperative of prioritizing rare disease therapies and streamlining regulatory processes. Craig Wilkinson from Novocure shared insights into their pioneering work in treating rare diseases like Glioblastoma, underscoring the importance of comprehensive investment in both drug and device innovation. Networking opportunities provided valuable exchanges with industry peers, such as Pavithra Emile and Devin Oot, offering insights into regulatory policies and decision-making processes. In summary, the event served as a poignant reminder of the immense potential within the New England region to drive innovation and address the unmet needs of individuals grappling with rare diseases. Through collaborative efforts across academia, industry, and regulatory bodies, we can continue to make strides in bringing hope and solutions to those in need. #RareDisease #Innovation #Biotech #Healthcare #Collaboration

As the 42nd annual J.P. Morgan Healthcare Conference takes place, we are reminded of the contributions of global health and life sciences industry leaders that are shaping the future of innovation in the field. With a growing and aging population, there is a larger need for more precise medicine. Carlos Murillo, President of Pfizer Spain, is a prime example of this effort as the company continuously invests in R&D: "Spain is one of our major markets globally, ranking among the top ten countries worldwide. This significant market size greatly impacts our sales, positioning us strongly in the business landscape. It is a key strength that propels us forward. Another key aspect is Spain's pivotal role in clinical trials. It's our second-largest global market for essential therapies in this domain. We invest substantially in clinical trials here, collaborating with 642 institutions on numerous medical research protocols. Spain's importance in this area is a competitive edge for Pfizer and the entire industry" - Carlos Murillo, President Pfizer Spain. Thank you Carlos Murillo for the insightful conversation with Executive Forecast Josef Gasse-Coope George Spirakis Ines Nandin Marta Diez Patrick van der Loo Rhulani Nhlaniki Erika Pagani

🙌🏼 At Bristol Myers Squibb we are writing a new chapter in our history that shows our commitment to #innovation, #diversity and #collaboration! 🗣️ This is reflected by Sandra Orta, General Manager of BMS Spain & Portugal, in this Executive Forecast interview where she shares her transformative vision and new #leadership style: 1️⃣ #Innovation drives the evolution of our company, focusing on therapeutic areas where there are unmet needs. Providing value where it is needed and being responsible for the sustainability of the system. 2️⃣ Close #collaboration with regulatory agencies, the scientific community, and government and #patient organisations enables us to move forward together, listening to their needs. 3️⃣ The importance of fostering #cultural change, empowering people, focusing on #diversity and eliminating inefficient hierarchies. 💬 In this sense, Sandra Orta stresses: "Hierarchy is one of the things I am trying to break and evolve. I believe in equality and that we all have the same voice, and we have to listen to each other. I strive to empower people to build a culture of speaking and trust where hierarchies are not important". 💫 Because it's not just our innovative #Science that is leading us to transform patients' lives! Our holistic approach is leading the way to a better future. 🔗 Access the full interview: https://lnkd.in/dNJF3R7v #BMSIberia #BMSPortugal #BMSEspaña #BMSCommunity #BMSTransformingLives #WorkingTogetherforPatients #BMSTransformingPatientsLives 

Science, research and manufacturing in Australia. AstraZeneca CEO, Pascal Soriot, ANZ CEO, Ben McDonald, and Director of Corporate Affairs, Penny George, met with the Hon. Ed Husic MP, Australian Minister for Industry and Science, to discuss science, research and manufacturing in Australia. We discussed the breadth of AstraZeneca’s presence in Australia, from clinical trials through to manufacturing. We also explored how greater collaboration between industry and government could shape the future landscape of science, research and manufacturing and advance better health for Australians.  Through concerted efforts together we can continue to unlock the power of what science can do. 

Pedersen & Partners and CMS Netherlands co-hosted this week’s M&A and Funding in Life Sciences Breakfast Seminar. The event provided a lively and agile atmosphere for representatives of well-known and international life sciences companies and scale-ups to discuss, debate, and network. 👨💼👩💼The event gathered more than 60 decision-makers to ensure a range of perspectives. The panel discussions were led by: Erik van den Berg (CEO, Memo Therapeutics AG); Martijn Boot (Head of Legal, Brocacef); Dr. Jan Groen (CEO, Intravacc); Jos Lunenberg (CEO, Surfix Diagnostics); and Koenraad Wiedhaup (CEO, Leyden Labs). 🎙️ The panel discussion was co-chaired by Pieter van Duijvenvoorde (Partner, Corporate / M&A Practice, CMS Netherlands); Ellen Gielen (Partner, Head of Lifesciences & Healthcare, CMS Netherlands); and Lydia van der Meulen (Client Partner, Head of Life Sciences & Healthcare Practice Group at Pedersen & Partners). The 🔝 takeaways from the event: 💼 M&A, investment and fundraising dynamics: the market has ‘normalised’ and last year proved difficult for fundraising, although there are funding opportunities to be found in the USA and Asia. In terms of deals, there is a noticeable shift to companies that are in a later stage of development. 🌍 External factors: the Netherlands may lose its ability to build innovations by bringing together (international) talent, (international) scientists and capital. 🚫 Regulatory constraints or threats affecting M&A and investments: the upcoming EU Pharma package will result in less access to new medicines for EU member states. 🚀 Exit strategies & market climate: exit strategies should be clear at an early stage. The exit environment has improved and an increase in IPOs is expected in 2025–26. Photo credits: CMS Netherlands

🌍 Join us at MEDICA 2024! We’re excited to announce we will be participating in MEDICA - Leading International Trade Fair (November 11-14 - Düsseldorf, Germany) 😀 MEDICA is where the global healthcare community gathers to exchange ideas, discover new technologies, and shape the future of medical diagnostics. It’s the ideal platform for us to showcase how our human Fc monoclonal antibodies are transforming the IVD landscape. 3 reasons to stand by our booth H56-1 (Hall 3) 👇 1️⃣ Advanced diagnostic applications: we’re pushing the boundaries of what’s possible in diagnostics, with human Fc mAbs that offer unparalleled specificity and reliability in detecting disease markers. 2️⃣ Real-world impact: from early disease detection to monitoring chronic conditions, our antibodies are making a tangible difference in patient outcomes. 3️⃣ Collaboration opportunities: whether you’re looking to enhance your diagnostic solutions or explore new partnerships, we’re eager to discuss how we can work together to innovate in the IVD space. Come visit us, and let’s explore how we can push the boundaries of diagnostics together. 🗨️ And if you'd like to book a time with our team to discuss in detail your needs and projects, contact Pauline Monsbrot See you in Düsseldorf! ✈️ #monoclonalantibodies #mabs #diagnosticsexcellence #IVD #invitrodiagnostic

💡 Had to share this whitepaper written by my colleagues! My colleagues Monique Marsh, Sebastian Daou, Ari King, MPH, Cassy Ingersoll. and Lisa Bailey, Ph.D. just released their most recent white paper about Diversity in Clinical Trials, which i believe it is a critical topic that should be on the agenda of all pharma / biotech leaders (or at least I hope!). There are several barriers to achieving clinical trial diversity, including the mistrust in the healthcare system, as discussed in the paper. Especially noteworthy are the tactics proposed to improve diversity, which include the creation of senior leadership roles responsible for trial diversity, allowing telehealth visits, broadening eligibility criteria, creating metrics to measure the success of diversity initiatives, among others. In case you would like to read the full paper, you can find it here: https://lnkd.in/dK5TK-aV Also, if you would like to learn more about how Trinity Life Sciences can help you make your clinical trials more inclusive do not hesitate to reach out. I would be happy to connect you with my colleagues! #lifesciences #diversity #clinicaltrials #inclusiveness #DEI